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Abstract: Mycobacterium tuberculosis (MTB) is a global heath epidemic, its threat 
amplified by HIV infection and the emergence of multidrug-resistant tuberculosis  
(MDR-TB). Interferon (IFN)-gamma release assays (IGRAs) have improved the accuracy 
of detection of MTB exposure in some subject groups as compared to the Tuberculin Skin 
Test (TST). However, as IFN-gamma is produced by both fully rested and more recently 
activated populations of memory T cells, it is not surprising that the measurement of this 
cytokine alone cannot accurately distinguish Latent TB Infected (LTBI) subjects from 
those with active (infectious) disease. Accurate and rapid diagnosis of infectious 
individuals would allow medication to be properly allocated and other actions taken to 
more effectively curtail MTB spread. Analysis of multi-cytokine profiles ex vivo after 
stimulation of PBMCs from LTBI and active MTB subjects indicate the real possibility of 
successfully discerning these two disease states within 24 hours of a subject’s blood draw. 
Due to the unparalleled sensitivity, low cost, and ease of use of Elispot assays, we propose 
that via a multiplex Elispot platform the accurate distinction of LTBI from active  
MTB-infected individuals is within reach. 
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1. Introduction 
Mycobacterium tuberculosis (MTB) is a global health crisis, with one in three individuals predicted 
to have been exposed to MTB worldwide. Of those exposed, eight million develop symptoms and 
approximately two million succumb to the infection each year. The predominance of HIV and MTB 
co-infection in many developing countries and the emergence of drug resistant MTB strains have 
contributed to these staggering global statistics [1].  
After MTB exposure, usually via inhalation, lung macrophages are infected, spurring inflammation 
and an adaptive immune response. MTB-antigen-specific immunity usually successfully controls the 
pathogen, although viable bacteria do remain in granulomas for extended periods of time [2]; this is 
known as latent TB infection (LTBI). Most LTBI individuals are asymptomatic for their lifetime, with 
only approximately 15% ever developing active disease [3]. However, in HIV-infected individuals, 
there is a 5–10% risk of conversion from LTBI to active disease each year [3]. It is those with active 
MTB that are most likely to spread the disease and pose the largest health risk to the community. 
The only effective vaccine to date is BCG (Bacille Calmette Guerin), which limits pediatric MTB 
but is not as effective in preventing adult pulmonary disease [4]. Also, treatment for MTB has not 
changed significantly since 1976 [3]. With a marginally effective vaccine and no new treatments on 
the horizon, a new sensitive and rapid method to distinguish LTBI from active (infectious) disease 
would allow quick treatment and containment of infectious individuals, limiting MTB spread  
and mortality. 
2. Current Methods to Detect MTB Exposure/Infection 
MTB infection is traditionally and still widely diagnosed using the Tuberculin Skin Test (TST).  
In this method, an individual is injected with Purified Protein Derivative (PPD) and evidence of 
antigen-specific immune memory is assessed via swelling of the injected site within 48 to 72 hours. 
The simplicity and ease of readout are clear advantages; however, TST often provides ambiguous 
results in immuno-suppressed individuals [3], and those never exposed to MTB but previously 
vaccinated with BCG can present with positive test results.  
In the last decade, new assays were FDA approved to diagnose MTB in the United States: the 
TSPOT™.TB (Oxford Immunotec), the QuantiFERON®-TB Gold (QFT), and the QuantiFERON®-TB 
Gold In-Tube (QFT-IT) (Cellestis Limited). In the TSPOT™.TB and QFT, blood is drawn from the 
subject and IFN-gamma is measured after stimulation of PBMC with Early Secreted Antigen Target 
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(ESAT-6) and Culture Filtrate Protein (CFP-10) antigens, both found within the RD1 (Region of 
Deletion 1) genomic segment of MTB. The QFT-IT includes the TB7.7p4 peptide coated to vacutainer 
tubes for cell stimulation without the need for cell isolation. These Elispot or ELISA-based methods, 
collectively referred to as IFN-gamma-release assays (IGRAs), offer noted advantages in the detection 
of latent MTB infection over TSTs. IGRAs demonstrate high specificity for MTB and, unlike the TST, 
are far less likely to give positive results from individuals who are BCG vaccinated and never MTB 
exposed. Also, the sensitivity of IGRAs increases the likelihood of detecting MTB infection in 
immuno-suppressed subjects, such as those who are HIV+ and are most likely to progress to active 
infection [5]. IGRAs clinical use is most noted due to its strong predictive value to active infection 
amongst MTB contacts [6] Another cytokine, IP-10, performs similar to the IGRAs for MTB diagnosis 
and positivity rates were less dependent on CD4 counts in HIV+ subjects, implicating this analyte as 
one of choice for detection of TB in immuno-suppressed individuals [7]. Both the IGRAs and IP-10 
release assays have improved the ability to detect MTB exposure as compared with TST; however, 
they cannot reliably distinguish between latent and active MTB infection [8,9]. Also, analysis of a 
large range of transcriptional biomarkers in whole blood revealed signatures of actively infected 
subjects that correlate with the severity of their radiological disease; some LTBI and actively infected 
patients were not distinguishable using this platform [10]. There is currently no standard test to 
determine latent (LTBI) from active (infectious) MTB.  
3. Limitations of IFN-gamma as the Sole Measurement of Immune Status 
When a naïve T cell encounters peptide antigen and MHC, it will differentiate into an  
antigen-experienced (memory) T cell. Depending on the cytokine milieu and other factors in the 
microenvironment at priming, T cells can differentiate into Type 1, Type 2, or other functional 
lineages, such as Th17 [11]. While most immune responses include Th1/Tc1 cells (the CD4 and CD8 
cells of the Type 1 lineage, respectively), and many of the T cells within that lineage secrete  
IFN-gamma upon re-stimulation ex vivo, these cells likely represent only one fraction of the composite 
T cell response induced by a pathogen or vaccine. Also, not all Th1/Tc1 cells secrete IFN-gamma upon 
re-stimulation [12,13]. In addition, other functions commonly associated with Type 1 T cells,  
such as cytotoxicity, are regulated and expressed independently of IFN-gamma in CD8 T cell 
populations [12,14,15]. Therefore, the numbers of IFN-gamma-producing cells can be a poor correlate 
of cytotoxic or “CTL” frequencies in one’s experimental system or patient sample. However, in many 
vaccine trials, infectious disease studies, and in the IGRAs, IFN-gamma is the sole immunological 
readout and therefore a considerable and important proportion of the immune response is not considered.  
Furthermore, as IFN-gamma can be rapidly produced by recently activated effector or fully rested 
memory T cells, measurement of only this one analyte will likely reveal very little about the state of 
infection/disease in an individual. The IFN-gamma response after ESAT-6 or CFP-10 stimulation are 
different in MTB subjects in different states of disease when measured ex vivo in one study [16] but 
not another [17]; this is consistent with the findings in other infections such as HIV, where there is no 
consistent association with peptide-specific IFN-gamma secretion and viral load [18].  
Therefore, while IFN-gamma measurement can serve as a useful biomarker of previous antigen 
encounter, its value when measured alone at determining disease state or vaccine efficacy is often 
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limited and can be very misleading. Multiple effector functions secreted by the composite  
MTB-specific T cell memory pool must be simultaneously measured to perform accurate T cell 
diagnostics of LTBI versus active MTB disease.  
4. Cytokine Analysis of the ex Vivo MTB-specific T Cell Response in LTBI, Active MTB Subjects 
In recent years, analysis of cytokines other than IFN-gamma and also multiple effector functions in 
combination from the MTB-specific immune response of LTBIs and active MTB subjects were 
compared. Some interesting trends are emerging to suggest that a functional bio-signature for LTBI 
subjects, distinct from active infected individuals, is attainable. 
4.1. IL-2, IFN-gamma, TNF-alpha, and the “Polyfunctional” T Cell 
Flow cytometric analysis allows the simultaneous measurement of multiple cytokines from 
individual T cells after short-term stimulation with MTB antigens. Comparison of the percentages of T 
cells secreting all possible combinations of IL-2, IFN-gamma, and TNF-alpha after ESAT-6 or CFP-10 
stimulation of PBMC from individuals with LTBI versus active MTB was performed. Higher 
percentages of CD4+ T cells that are “polyfunctional” triple producers (IL-2+, IFN-gamma+,  
TNF-alpha+) were found in the PBMC of LTBIs compared with active MTB subjects [17,19], with 
statistical significance in one study [17]. Also, longitudinal analysis of MTB-specific T cell responses 
from subjects with active disease (before and after treatment) found that the proportion of IL-2+,  
IFN-gamma+, TNF-alpha+ triple producing cells was higher, on average, after treatment [17,19]. 
Measurement of MTB-specific single-positive TNF-+ CD4 T cells showed the best discriminatory 
potential for these two disease states in one study [17]. Also, there is a positive correlation of ex vivo 
proliferative capacity of MTB-specific T cells and the number of TNF-alpha+ IL-2+ IFN-gamma+ 
cells after MTB antigenic stimulation [19]. Similar to this flow cytometric data, two-color fluorescent 
Elispot assays for IFN-gamma and IL-2 found more dual producing cells in the LTBIs compared with 
active TB subjects; furthermore, this signature of IFN-gamma only cells in untreated MTB  
subjects with active disease shifted to dual IFN-gamma+ IL-2+ T cells in the months after treatment 
was initiated [20]. Taken together, these data suggest that similar to what is found in other infectious 
diseases [21,22], high bacterial load is congruent with functional and proliferative exhaustion of 
antigen-specific T cells, with MTB-specific T cells likely returning to a resting state after treatment 
and re-acquiring the ability to secrete multiple cytokines and proliferate when antigen is re-
encountered. 
While analysis of TNF-alpha and IL-2 in addition to IFN-gamma shows great potential to 
conclusively distinguish LTBI from active MTB subjects, either no differences in the profile of the  
IL-2+, IFN-gamma+, TNF-alpha+ responses to ESAT-6 or CFP-10 between active and LTBI  
subjects [23] or that the IL-2+, IFN-gamma+, TNF-alpha+ T cell frequencies were actually higher in 
the active TB subjects [24] has been reported as well. Use of recombinant proteins in re-stimulation 
cultures, length and nature of stimulation assays, and differences in patient cohorts and number of 
events collected in flow cytometric assays could account for why these results differ from other 
findings. Alternatively, it is possible that T cell functions from other effector lineages must be 
measured to reliably determine LTBI versus active MTB disease.  
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4.2. IL17 
IL17 is a cytokine associated with inflammation and anti-viral responses, and is produced by the 
Th17 lineage of memory T cells. In MTB infection, the frequency of IL17-producing CD4+ T cells 
after PMA and Ionomycin stimulation was significantly lower in active MTB subjects compared to 
both LTBI and healthy donors [25]; the frequency of IL17+ T cells after BCG stimulation was also 
found to be lower in active MTB subjects compared with healthy controls, and IL17 was produced by 
T cells within PBMC of MTB subjects after ESAT-6/CFP 10 peptide stimulation [26] Also, IL-17 
production by CD4+ T cells in response to CFP-10/ESAT-6 peptides was detected from pleural fluid 
samples from subjects with tuberculous pleurisy (TBP) [27]. This cytokine therefore may prove an 
important component of anti-MTB immunity and useful for detection of LBTI versus active MTB 
disease states.  
4.3. Type 2 Cytokines/ T regulatory cells (Tregs) 
While Th1 cytokines (IFN-gamma, TNF-alpha) and the Th17 cytokine IL-17 are well established as 
integral components of a successful immune response to infection, these functions can cause significant 
immuno-pathology to the host. Therefore, T cell effector functions with immunosuppressive roles, 
such as IL-4, IL-5, IL-10, IL-13, TGF-beta and the direct T cell inhibitory T regulatory cells (Tregs), 
are often a substantial and integral component of an antigen-specific immune response. TGF-beta and 
IL-10 are produced in response to PPD from PBMC of infected subjects ex vivo [28]. Cytometric Bead 
Array assays of culture supernatants after PBMC stimulation in Quantiferon® Gold In-Tube tests 
reveal significantly more IL-4 production from the PBMC of active compared with latent TB subjects, 
with IFN-gamma not significantly different between the two groups [29]. Also, 20–25% of pulmonary 
TB patients with newly active disease present a diminished TST response [30]; these negative TSTs 
associate with lower IFN-gamma T cell responses to PPD in ex vivo re-stimulation assays [28,31]. 
Negative TST results also routinely appear in subjects with miliary TB and other extra pulmonary 
forms of disease, with reversion to positive responses after MTB treatment [30]. IL-10 and TGF-beta 
are elevated in active MTB subjects and associated with suppression of MTB-specific immune 
responses [28]. Also, FOXP3+ CD4 T cells are higher in frequency in pleural fluid compared with 
peripheral blood [25]; these findings implicate a role of Tregs at the site of MTB replication. The 
relative Treg frequencies in the PBMC of LTBI and active MTB subjects are not yet clear.  
This immunosuppressive arm of the immune response may arise to dampen the inflammation and 
reduce immuno-pathology during onset of active disease, or alternatively, MTB may have evolved to 
induce type 2 responses to inhibit autophagy in macrophages, as IFN-gamma promotes while IL-4 and 
IL-13 directly inhibit this process [32]. Regardless of the cause, the apparent emergence of these  
Type 2 cytokines render them attractive candidates for analysis when seeking to define bio-signatures 
of LTBI and active MTB disease states for immunodiagnostics.  
  
Cells 2012, 1 94 
 
 
5. The Power of a Multiplexed Elispot Platform to Distinguish LTBI from Active MTB Disease  
Taken together, the findings of Th1, Th2, Th17, and other effector functions in LTBI as compared 
with active MTB subjects indicate that combinational analysis of multiple functions will likely provide 
a cytokine bio-signature that will conclusively distinguish these two states of infection. Elispot assays 
present clear advantages over other methods currently used for analysis of ex vivo T cell effector 
functions, and we propose Elispots are the platform of choice to distinguish LTBI versus active  
MTB infection.  
5.1. Elispot Versus Flow Cytometry (Intracellular Cytokine Staining) 
Elispots, like flow cytometry-based Intracellular Cytokine Staining (ICS), can directly determine 
the frequency of immune cells responding to a particular antigen, a core competency for immune 
diagnostics. In fact, while the putative naïve T cell repertoire is comprised of a vast number (≥1012) of 
TCR specificities, for any single infective agent, the frequency of circulating antigen-specific memory 
cells is quite low, typically in the range of 1:10,000–1,000,000. While capable of single-cell resolution, 
detection of this rare cell pool can be a challenge for flow cytometry, whose lower limit of sensitivity 
for identifying functional T cell frequencies is reported to be 0.02% [33]. By contrast, in routine 96-
well Elispot assays, limits of 0.00025% (1 spot forming unit per 400,000 input PBMC) are commonly 
observed [34]; this equates to a near 100-fold greater detection sensitivity compared with flow 
cytometry. In fact, the Elispot assay has demonstrated signal linearity for cultures in the range of  
1 × 106 PBMC [35]; thus, the only true constraint on this technique appears to be the number of cells 
available for testing, size can also be increased to accommodate larger cell numbers. Also, Elispots are 
currently one of the only techniques permitting quantification of secretory activity at the single cell 
level. Since detection by ICS occurs prior to cytokine release, there is the potential for misleading 
results due to post-translational modulation of protein expression [36]. Further, while both ICS and 
Elispots measure cytokine secretion independent of kinetics within the culture period, a significant fact 
given the unsynchronized nature of the responding T cell pool, the duration of the ICS assay is limited 
by the toxicity of protein transport inhibitors. Therefore, detection of some cytokines may not be 
possible when ICS is used. 
5.2. Elispot Versus Supernatant Analysis (ELISA, Multiplex Bead Array Technology) 
While ELISAs and bead-based measurement of cytokines from culture supernatants offer some 
advantages [37], there are limitations that preclude their acceptance as a T cell diagnostic platform for 
MTB disease states. For example, bulk supernatant assays lack the sensitivity for extremely low 
frequency signal detection. Spot size gating of Elispots using quantitative image analysis platforms 
permits a clear distinction between the diagnostically relevant large T cell-derived spots and smaller 
non-specific bystander spots. Since bulk assays cannot provide information on a ‘per cell’ basis, the 
contribution of Ag-specific responses may be diluted by background from the innate immune system, 
resulting in overall signal flattening; this issue is most relevant in PBMC cultures where the  
Ag-specific T cell pool is vastly outnumbered. The sensitivity threshold for cytokine measurements in 
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culture supernatants is further diminished in these assays by analyte dilution in the surrounding milieu, 
absorption by bystander cells, and enzymatic degradation.  
5.3. Elispots for Multiplex Analysis 
Elispots not only provide superior quantitative performance, they are also amenable to multiplex 
analyses carried out simultaneously (single well), in parallel wells, or in multi-color assays.  
Given the relatively small sample size required per test, multiple cytokine Elispots can be performed in 
parallel. Well established dual and even triple-color Elispots, both enzymatic and fluorescent, allow 
multiparameter resolution at the single cell level and are currently used in many research settings, 
including clinical diagnostics as well as therapeutic design [38–40]. The ever-expanding availability of 
discrete fluorochromes, when combined with multi-laser instrumentation and fully automated sample 
acquisition and data analysis, provide the framework for unsurpassed multi-functional analysis of 
antigen-specific T cell frequencies in the near future. 
5.4. Elispots in Limited Resource Settings 
Beyond performance criteria, the Elispot assay possesses a number of other characteristics 
favorable for widespread adoption in developing countries where MTB is most devastating. Compared 
with flow cytometry, Elispots require one-tenth less cells per test, a fact that is crucial under conditions 
where samples are precious (remote testing) and/or limiting (pediatric test subjects). Smaller sample 
sizes also mean less reagents used per test. Also, Elispot data acquisition/analysis is far easier to 
perform, less time consuming, and dramatically lower in cost than flow cytometry. In fact, data from a 
96-well Elispot plate can be acquired and analyzed by an image-based platform, such as the 
ImmunoSpot, in the same amount of time it takes a skilled flow cytometer operator to collect one 
sample. Also, while flow cytometry struggles with a lack of user-independent gating capabilities, and 
therefore suffers from inter-user and inter-lab subjectivity [41], automated platforms promote the 
standardization of Elispot data analysis and greater reproducibility across sites. These features make 
the Elispot assay the ideal choice for high-throughput testing applications as could be applied in  
large-scale subject profiling. 
6. Conclusions 
When assay sensitivity, ease of use in the field, and cost are all taken into consideration, a 
combination Elispot platform is likely the superior choice for the development of a multifunctional T 
cell assay to distinguish LTBI from active MTB disease status. Due to the wide variation in cytokine 
secreting cells per donor within both the LTBI and active MTB subjects [17], we predict that the 
resolving bio-signatures will be derived from a potentially complex ratio of the frequencies for a 
number of distinct cytokine–producing T cell types. For this to succeed, the initial enabling phase 
should be a large scale screen of the ex vivo functional profiles from LTBI and active MTB subject 
groups. To date, one study has compared multi-functional responses (via a Luminex bead array 
platform) from subject groups containing 12 active TB and 32 LTBIs. Despite the small numbers, the 
combined use of IL-15 and MCP-1-determined LTBI from active MTB disease states with 88% and 
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83% accuracy, respectively [29]. Once an accurate panel of distinguishing secreted bio-markers is 
found, work can begin on converting this assay from cell-based to serum profiling formats, ultimately 
resulting in the development of rapid remote-applicable testing platforms.  
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